2016 Review: Refocus, Reduce, Reform The Watchwords In Japan

While reimbursement pricing issues and policies dominated the Japanese pharma market in 2016, there was also notable commercial activity during the year, although this was more about refocusing and reducing rather than major mergers and acquisitions.